<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486433</url>
  </required_header>
  <id_info>
    <org_study_id>OM-EPA-007</org_study_id>
    <nct_id>NCT01486433</nct_id>
  </id_info>
  <brief_title>The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects</brief_title>
  <official_title>An Open-Label, Randomized, 2-Way Crossover Study to Evaluate the Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the effect of multiple doses of Epanova® (omega fatty&#xD;
      acids) on the pharmacokinetics (PK) of multiple 40 mg doses of simvastatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is testing the hypothesis that there is no interaction between Epanova and&#xD;
      concomitant administration of simvastatin and aspirin. No drug interaction will be claimed&#xD;
      if, following concomitant administration of simvastatin, aspirin and Epanova or only&#xD;
      simvastatin and aspirin, the 90% confidence intervals (CIs) for the geometric mean ratios&#xD;
      (GMRs) of the back-transformed PK parameters, area under the plasma concentration versus time&#xD;
      curve (AUC0-tau) and concentration at the end of a dosing interval (Cmax,ss), for simvastatin&#xD;
      and beta- hydroxysimvastatin acid,fall within 80%-125%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-tau)</measure>
    <time_frame>14 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-tau)for simvastatin and beta- hydroxysimvastatin acid, measured over the 24 hour period after the 14th dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at the end of a dosing interval (Cmax,ss) for simvastatin and beta- hydroxysimvastatin acid,</measure>
    <time_frame>14 days</time_frame>
    <description>Maximum measured plasma concentration for simvastatin and beta- hydroxysimvastatin acid,during the 0-24 hour dosing interval for the 14th simvastatin dose (Day 14)measured over the 24 hour period after the 14th dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Epanova and Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40 mg (1 tablet) simvastatin once a day</description>
    <arm_group_label>Epanova and Simvastatin</arm_group_label>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid (ASA)</intervention_name>
    <description>81 mg aspirin (1 tablet), once a day, co-administered with simvastatin</description>
    <arm_group_label>Epanova and Simvastatin</arm_group_label>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omefas</intervention_name>
    <description>4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin</description>
    <arm_group_label>Epanova and Simvastatin</arm_group_label>
    <other_name>Epanova</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must fulfil all of the following inclusion criteria to be eligible for&#xD;
        participation in the study, unless otherwise specified:&#xD;
&#xD;
          1. Healthy adult male or female volunteers, 18-55 years of age, inclusive.&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 18 and ≤ 29.9 (kg/m2).&#xD;
&#xD;
          3. Medically healthy with clinically insignificant screening results. Hemoglobin must be&#xD;
             ≥ the lower limit of normal.&#xD;
&#xD;
          4. Continuous non-smokers who haven't used nicotine-containing products for at least 6&#xD;
             months prior to the first dose.&#xD;
&#xD;
          5. Voluntarily consent to participate in the study and to follow the restrictions and&#xD;
             procedures outlined for the study.&#xD;
&#xD;
          6. Females must be of non-childbearing potential, and have undergone sterilization&#xD;
             procedures at least 6 months prior to the first dose or be postmenopausal with&#xD;
             amenorrhea for at least 2 years prior to first dosing and follicle stimulating hormone&#xD;
             (FSH) serum levels ≥ 40 mIU/mL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects may be excluded from the study if there is evidence of any of the following&#xD;
        criteria at screening, check-in, or at any time during the study, as appropriate:&#xD;
&#xD;
          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             haematological, gastrointestinal (GI), endocrine, immunologic, dermatologic,&#xD;
             neurological, or psychiatric disease in the opinion of the PI.&#xD;
&#xD;
          2. Personal or familial history of bleeding disorder(s), thromboembolic disease, clinical&#xD;
             GI bleeding, or any history of GI surgery except uncomplicated appendectomy or&#xD;
             cholecystectomy, or colorectal surgery for polyps, nonmalignant tumors, or&#xD;
             diverticula.&#xD;
&#xD;
          3. Positive urine drug/alcohol testing at screening or check-in.&#xD;
&#xD;
          4. Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C antibodies (HCV).&#xD;
&#xD;
          5. History or presence of alcoholism or drug abuse within the past 2 years.&#xD;
&#xD;
          6. Subject has been on a special diet (for whatever reason) within the 28 days prior to&#xD;
             the assigned first dose of study drug or anytime during the study.&#xD;
&#xD;
          7. Known sensitivity or allergy to soybeans, fish, and/or shellfish.&#xD;
&#xD;
          8. Hypersensitivity or idiosyncratic reaction to compounds related to simvastatin (i.e.,&#xD;
             HMG-CoA reductase inhibitors) and/or Epanova® and/or aspirin.&#xD;
&#xD;
          9. Subject is a female who is pregnant or lactating.&#xD;
&#xD;
         10. Use of any prescription medication within 14 days prior to the first dose.&#xD;
&#xD;
         11. Use of any over-the-counter (OTC) medication, including herbal products (e.g.,&#xD;
             bromelains, danshen, dong quai [Angelica sinensis], garlic, ginko biloba, ginseng, and&#xD;
             St. John's wort, NSAIDs), vitamin K or food supplements (especially omega-3-fatty&#xD;
             acids) within the 7 days prior to first dosing.&#xD;
&#xD;
         12. Use of any drugs known to significantly inhibit [strong or moderate] or induce liver&#xD;
             enzymes involved in drug metabolism [CYP P450]) within 30 days prior to check-in.&#xD;
&#xD;
         13. Donation of blood or significant blood loss within 56 days prior to check- in.&#xD;
&#xD;
         14. Donation of plasma within 7 days prior to check-in.&#xD;
&#xD;
         15. Participation in another clinical trial within 30 days prior to check-in.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Davidson, MD, FACC</last_name>
    <role>Study Director</role>
    <affiliation>Omthera Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eicosapentaenoic acid</keyword>
  <keyword>docosapentaenoic acid</keyword>
  <keyword>arachidonic acid</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

